Biomedical Catalyst 2018 round 2: late stage
Fund Name: late stage
Project Length: 12-36 months
Project Value: Share of £10m
The late stage award supports projects which test a well-developed concept. It should show its effectiveness in an environment that is relevant to the use of the product or process.
A late stage project can include:
- initial human proof-of-concept studies
- demonstration of clinical utility and effectiveness
- demonstration of safety and efficacy (including phase I and II clinical trials)
- developing production mechanisms
- market testing
- intellectual property protection
These solutions should be innovative healthcare technologies, products or processes that will help provide at least one of the following:
- disease prevention and proactive management of health and chronic conditions
- earlier and better detection and diagnosis of disease, leading to better patient outcomes
- treatments that either change underlying disease or offer potential cures
Innovate UK will support projects from any sector or discipline, including (but not limited to):
- advanced therapies (cell and gene therapy)
- precision medicine (both therapy and diagnostic components)
- digital health
- medical technologies and devices
If you choose the innovation area ‘Diagnostics, medical technology and devices’, please indicate within the scope whether your project falls within ‘Diagnostics’ or ‘Medical technology and devices’.
The work required will depend on the maturity and intended application of the technology you are developing in your project. Your late stage project must build on prior credible research on your technology, product prototype or process. This prior research should include a demonstration or validation in an appropriate model system.
Innovate UK expect projects to range in size from £200,000 to £4 million (total project costs). Projects should last 12 to 36 months and must start before 1 July 2019.
An SME business can:
- take part in up to 3 applications in this competition round, although you can only be the lead partner in one application in this round
- lead only one active project in any one Biomedical Catalyst award at any time
The exception to the rule on leading only one active project is when a new project is a direct progression from one award to the next category of awards. For example, you may already hold both an early stage and a late stage award. When the early stage project finishes, you may apply in this round for a late stage award to continue that specific programme of work while still holding your original late stage award. We will ask you to provide evidence that you have enough resources to run 2 projects at the same time.
If you applied to a previous competition as the lead or sole company and were awarded funding by Innovate UK, but did not make a substantial effort to exploit that award, we will award no more funding to you, in this or any other competition. You will not be able to contest our decision. We will:
- assess your efforts in the previous competition against your exploitation plan for that project
- review the monitoring officers’ reports and any other relevant sources for evidence
- document our decision, which will be made by 3 team members
- communicate our decision to you in writing